Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cp-724714. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-724714 SCHEMBL4617807 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL29561705 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL95109 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL4796165 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6169707 | 0.99 | ERBB2 (0.98) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6169715 | 0.99 | ERBB2 (0.98) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168343 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168355 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168480 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168463 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2026-05-07 | — | — | US | disclosed |
| WO-2026044398-A1 | SALTS OF 5-CHLORO-2-FLUORO-N-(2-FLUORO-4-(3-METHYL-4-[(1-METHYLPIPERIDIN-4-YL)OXY]-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)PHENYL)BENZENE SULFONAMIDE AND CRYSTALLINE FORMS THEREOF | THRYV THERAPEUTICS INC. (CA) | 2026-03-05 | — | — | WO | disclosed |
| WO-2025090966-A1 | MEK INHIBITORS, ALONE OR IN COMBINATION WITH CDK4/5 INHIBITORS, FOR USE IN TREATING CANCER | VEVO THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-11672812-B2 | Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer | CITY OF HOPE (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672812-B2 | Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer | FLT3, ABL1, TNNI3K | ERBB2 34/4885EGFR 184/4885FECH 3676/4885 |
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | FUCA2, LNPEP, EEA1 | ERBB2 988/4885EGFR 746/4885FECH 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.